Tislelizumab
Randomized
Seventh Medical Center of PLA General Hospitalmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Randomized cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Probio-M9 Seventh Medical Center of PLA General Hospital | Phase 2 | CCC |
Yangxue Qingnao Pills Dongzhimen Hospital, Beijing | Phase 2 | CCC |
Same molecule, other indications
Tislelizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →